Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | February 12, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date February 12, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,122.709 |
Reported balance
After 2026-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-14 · Exercise / conversion · Acquired 117 · Balance 2,122.709 F1: Includes a total of 49.709 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,291.709 |
Reported balance
After 2026-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 169 · Balance 2,291.709 |
| Common StockSEC Table I · non-derivative | Direct | 2,592.709 |
Reported balance
After 2026-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-14 · Exercise / conversion · Acquired 301 · Balance 2,592.709 |
| Common StockSEC Table I · non-derivative | Direct | 2,959.709 |
Reported balance
After 2026-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-02-14 · Exercise / conversion · Acquired 367 · Balance 2,959.709 |
| Common StockSEC Table I · non-derivative | Direct | 3,964.709 |
Reported balance
After 2026-02-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-02-14 · Exercise / conversion · Acquired 1,005 · Balance 3,964.709 |
| Common StockSEC Table I · non-derivative | Direct | 3,088.709 |
Reported balance
After 2026-02-14 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-02-14 · Tax withholding · Disposed 876 · Balance 3,088.709 F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 4,625 |
Reported balance
After 2026-02-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-12 · Grant · Acquired 4,625 · Balance 4,625 F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $617.20 · Expires 2036-02-11 | Direct | 162 |
Reported balance
After 2026-02-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-12 · Grant · Acquired 162 · Balance 162 F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,094 |
Reported balance
After 2026-02-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-12 · Grant · Acquired 1,094 · Balance 1,094 F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,620 |
Reported balance
After 2026-02-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-12 · Grant · Acquired 1,620 · Balance 1,620 F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-14 · Exercise / conversion · Disposed 117 · Balance 0 F7: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 169 |
Reported balance
After 2026-02-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-14 · Exercise / conversion · Disposed 169 · Balance 169 F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 602 |
Reported balance
After 2026-02-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-02-14 · Exercise / conversion · Disposed 301 · Balance 602 F9: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,101 |
Reported balance
After 2026-02-14 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-02-14 · Exercise / conversion · Disposed 367 · Balance 1,101 F10: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-14 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-02-14 · Exercise / conversion · Disposed 1,005 · Balance 0 F11: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 49.709 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.
F2: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
F3: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
F4: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
F5: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027.
F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027.
F7: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.
F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.
F9: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2025.
F10: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
F11: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,005 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 15 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F11 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F11 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 14 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101 Underlying: Common Stock · 367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 13 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2025. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2025. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 12 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169 Underlying: Common Stock · 169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 11 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 876 | $629.35 | $551,310.60 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 6 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,088.709 F2 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,005 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 5 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,964.709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 4 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,959.709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 3 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,592.709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 2 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,291.709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · nonDerivative · entry 1 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,122.709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 49.709 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 10 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Stock · 1,620 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 9 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,094 Underlying: Common Stock · 1,094 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 8 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:31 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,625 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000025 · wk-form4_1771374661.xml · derivative · entry 7 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,625 Underlying: Common Stock · 4,625 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 14 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 13 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338 Underlying: Common Stock · 170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 12 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2025. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2025. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 11 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117 Underlying: Common Stock · 117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vests in four equal annual installments beginning on February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vests in four equal annual installments beginning on February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vests in four equal annual installments beginning on February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 10 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four equal annual installments beginning on February 14, 2022. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four equal annual installments beginning on February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four equal annual installments beginning on February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 441 | $444.53 | $196,037.73 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 6 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,956 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 5 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 4 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 3 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 2 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · nonDerivative · entry 1 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,468 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 9 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468 Underlying: Common Stock · 1,468 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 217 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 8 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 Underlying: Common Stock · 217 shares Expires 2035-02-12 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 6,320 | $0.00 Strike: $459.76 | $0.00 |
DisclosureSEC source: 0000874716-25-000028 · wk-form4_1739933022.xml · derivative · entry 7 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,320 Underlying: Common Stock · 6,320 shares Expires 2035-02-12 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · derivative · entry 3 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments beginning on September 1, 2021. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 48 | $481.33 | $23,103.84 |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · nonDerivative · entry 2 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913 F2 · price: Closing price of Issuer common stock on August 30, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:20 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 164 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000127 · wk-form4_1725488990.xml · nonDerivative · entry 1 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11 shares purchased under the Issuer's Employee Stock Purchase Plan June 28, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 10 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508 Underlying: Common Stock · 170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four equal annual installments beginning on February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 118 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 9 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 Underlying: Common Stock · 118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four equal annual installments beginning on February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four equal annual installments beginning on February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four equal annual installments beginning on February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 8 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80 Underlying: Common Stock · 80 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four equal annual installments beginning on February 14, 2022. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four equal annual installments beginning on February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four equal annual installments beginning on February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 7 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,204 Underlying: Common Stock · 1,204 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 178 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 6 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178 Underlying: Common Stock · 178 shares Expires 2034-02-13 F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2028. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 5,407 | $0.00 Strike: $560.56 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · derivative · entry 5 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,407 Underlying: Common Stock · 5,407 shares Expires 2034-02-13 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2025. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 117 | $560.56 | $65,585.52 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · nonDerivative · entry 4 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 786 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · nonDerivative · entry 3 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 118 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · nonDerivative · entry 2 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:58 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 80 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000042 · wk-form4_1708124258.xml · nonDerivative · entry 1 Schreck Michael · CIK 0002004990 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.